stockrowRegeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) EBITDA
Regeneron Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was $4.1B, down 7.87% from $4.5B in fiscal 2024. Over the twelve months to 30 September 2026 it was $5.4B. Over the past ten years it has ranged from $1.3B (fiscal 2015) to $9.2B (fiscal 2021); the current reading is higher than 64% of that period. Regeneron Pharmaceuticals, Inc. ranks 1st of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $4.1B | (7.87%) |
| FY2024 | $4.5B | 0.12% |
| FY2023 | $4.5B | (12.05%) |
| FY2022 | $5.1B | (44.98%) |
| FY2021 | $9.2B | 142.18% |
| FY2020 | $3.8B | 57.53% |
| FY2019 | $2.4B | (9.79%) |
| FY2018 | $2.7B | 20.56% |
| FY2017 | $2.2B | 55.02% |
| FY2016 | $1.4B | 8.18% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $2.2B | 53.06% |
| Jun 2026 | $1.4B | 84.99% |
| Mar 2026 | $766.1M | (25.25%) |
| Dec 2025 | $1.0B | (11.91%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $5.4B |
| VRTX Vertex Pharmaceuticals Incorporated compare | $4.5B |
| ARGX argenex SE compare | $1.7B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.4B |
| GMAB Genmab A/S Sponsored ADR compare | $1.2B |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| RVMD Revolution Medicines, Inc. compare | −$1.6B |
| MRNA Moderna, Inc. compare | −$3.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on REGN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement